A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.

Lessons Learned: This study is a rare example of effective doses of both targeted agents being both administered and tolerated.This combination should not be used in melanoma.

Background: Sorafenib and bortezomib affect BCL family member expression.